Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121
Authors:
Preprint
Abstract
More than 1,200 variants of the cystic fibrosis transmembrane conductance regulator gene ( CFTR ) are associated with cystic fibrosis (CF), an autosomal recessive pulmonary disease affecting over 100,000 people. Most people with CF bear a common CFTR variant (F508del) that can be treated with therapeutics containing “correctors” that suppress the misfolding of the CFTR chloride channel. However, the pharmacological responsiveness of other rare CF variants can vary tremendously. The approval of VX-121, a VX-445 analog that serves as a key component of Alyftrek TM , potentially provides a new therapeutic option for those with rare CF variants. Nevertheless, it remains unclear whether VX-121 offers superior rescue across the entire spectrum of rare CF variants. In this work, we use deep mutational scanning (DMS) to survey the impact of VX-121 on the plasma membrane expression of 232 rare CF variants. Our results show that VX-121 generally enhances CF variant expression more than VX-445 and is most potent towards variants with mutations in the first membrane spanning domain (MSD1). However, we identify one variant (Y1032C) with diminished proteostatic and functional selectivity for VX-121 relative to VX-445. Computational docking suggests that the native Y1032 side chain forms favorable interactions with VX-121 that are disrupted by this mutation in a manner that alters its coordination. Finally, using photo-crosslinking, we show that VX-121 avoids a key off-target interaction of VX-445. Together, our findings provide new insights into the similarities and differences between current approved CF therapeutics.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL167046)
This publication has 38 references indexed in Scilit:
- General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variantsCell Chemical Biology, 2023
- Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022
- Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19Clinical Pharmacology & Therapeutics, 2022
- Entering the era of highly effective modulator therapiesPediatric Pulmonology, 2021
- The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescueJournal of Biological Chemistry, 2021
- Cell‐ and Tissue‐Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase InhibitorChemistry – An Asian Journal, 2018
- Conformational Changes of CFTR upon Phosphorylation and ATP BindingCell, 2017
- Molecular Structure of the Human CFTR Ion ChannelCell, 2017
- Atomic Structure of the Cystic Fibrosis Transmembrane Conductance RegulatorCell, 2016
- Rosetta Ligand Docking with Flexible XML Protocols2011